$8.83
0.68%
Downside
Day's Volatility :3.94%
Upside
3.29%
57.87%
Downside
52 Weeks Volatility :80.72%
Upside
54.24%
Period | Pepgen Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -46.71% | 5.1% | 0.0% |
6 Months | -37.73% | 4.9% | 0.0% |
1 Year | 39.94% | 16.6% | 0.0% |
3 Years | -25.8% | 13.2% | -22.3% |
Market Capitalization | 287.8M |
Book Value | $4.76 |
Earnings Per Share (EPS) | -3.31 |
Wall Street Target Price | 19.6 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -31.89% |
Return On Equity TTM | -58.97% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -94.4M |
Diluted Eps TTM | -3.31 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.16 |
EPS Estimate Next Year | -2.82 |
EPS Estimate Current Quarter | -0.72 |
EPS Estimate Next Quarter | -0.73 |
What analysts predicted
Upside of 121.97%
Sell
Neutral
Buy
Pepgen Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Pepgen Inc. | -0.56% | -37.73% | 39.94% | -25.8% | -25.8% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Pepgen Inc. | NA | NA | NA | -3.16 | -0.59 | -0.32 | NA | 4.76 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Pepgen Inc. | Buy | $287.8M | -25.8% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
RA Capital Management, LLC
Suvretta Capital Management, LLC
Viking Global Investors LP
Perceptive Advisors LLC
Adage Capital Partners Gp LLC
BlackRock Inc
Organization | Pepgen Inc. |
Employees | 72 |
CEO | Dr. James G. McArthur Ph.D. |
Industry | Services |
Telecom Argentina S.a.
$8.83
-0.34%
Jianzhi Education Technology Group Company Ltd.
$8.83
-0.34%
Regis Corp
$8.83
-0.34%
Gladstone Land Corporation
$8.83
-0.34%
Papa John's International Inc.
$8.83
-0.34%
Sunlands Online Education Group
$8.83
-0.34%
Gigacloud Technology Inc
$8.83
-0.34%
Noodles & Co
$8.83
-0.34%
Madison Square Garden Entertainment Corp
$8.83
-0.34%